Ascendis Pharma stock
ASNDNASDAQAscendis Pharma A/S, HealthcareISIN DK0060615755
69Score 69 out of 100, Neutral
Price and trend
79 / 100
Price history
+29% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 8.3% above it.
Since February 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 70).
The price is 6.5% below its 52-week high. Largest decline in 12 years: 62% (December 2020 to April 2023).
Chart figures for advanced users
- SMA 50$242.59
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$239.37
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$196.63
- The lowest closing price of the last twelve months.
- Resistance$277.18
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ascendis Pharma A/S belongs to the Biotechnology industry (Denmark) and, with a market value of $17.06B, is number 22 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $769.67M (up 90.2% year on year) and a loss of $243.72M.
- MEQIRI Score 69 out of 100 (Neutral): rank 150 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $324.09, with the price 20% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 150.9% a year since 2020, Biotechnology median 19.7%.Growth 70
- High marginNet margin 71.7% over the last 12 months, Biotechnology median −93.3%.Profitability 98
- More cash than debtCash $903.43M, financial debt $500.59M.Stability 62
Weaknesses
- DilutionShare count up 20% since 2020.Capital allocation 52
Its standout strengths are profitability and momentum, while fundamentals holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $249.30 and expensive above $462.98 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $386.09 (cash-flow model) and $262.08 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.4%. At 8.4% the fair value would be $292.56, at 6.4% it would be $370.52.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 115% on the twelve months before. Revenue has grown strongly since 2012, at around 34% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 85%, operating −19%, net −32%. Last 12 months: net 72%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- No date announced.
- Last reported
- 12 Nov 2026EPS reported 1.24 (expected 0.89)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 4.3% since 15 Oct 2026.
- Earnings per share
- 14.52+4.3%
- Revenue
- $1.51B+0.5%
- Earnings per share
- 9.1+0.5%
- Revenue
- $2.22B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −2.7%Expects operating cash flow of more than EUR 500 million this year; YORVIPATH to grow as in prior quarters and SKYTROFA revenue to be relatively stable.
“With respect to our cash flow guidance, just to be clear, greater than EUR 500 million, I thought you -- I heard you say EUR 100 million, so greater than EUR 500 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $777,067 in total. 2 insiders sold, $872,905 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Bodenhoff MadsSale
8 Sept 2026, SVP & PAO
- Shares
- 3,000
- Price
- $270.19
- Value
- $810,570
- Holtug LarsSale
2 Sept 2026, Board
- Shares
- 236
- Price
- $264.13
- Value
- $62,335
- Bienaime Jean JacquesPurchase
14 Aug 2026, Board
- Shares
- 2,000
- Price
- $246.33
- Value
- $492,654
Show 4 more
- Smith Scott ThomasPurchase
2 Jun 2026, EVP & Chief Financial Officer
- Shares
- 100
- Price
- $219.00
- Value
- $21,900
- Bienaime Jean JacquesPurchase
29 May 2026, Board
- Shares
- 500
- Price
- $223.12
- Value
- $111,562
- Smith Scott ThomasPurchase
29 May 2026, EVP & Chief Financial Officer
- Shares
- 250
- Price
- $223.32
- Value
- $55,830
- Bienaime Jean JacquesPurchase
26 May 2026, Board
- Shares
- 400
- Price
- $237.80
- Value
- $95,121
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ascendis Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Alnylam PharmaceuticalsALNY $21.41B57
- Innovent Biologics1801.HK $19.29B61
- ExelixisEXEL $17.77B90
- Neurocrine BiosciencesNBIX $17.65B77
- Jazz PharmaceuticalsJAZZ $15.93B66
- BridgeBio PharmaBBIO $15.49B50
- Sichuan Kelun-Biotech Biopharmaceutical6990.HK $13.99B49
- Kymera TherapeuticsKYMR $13.5B45
ETFs that hold Ascendis Pharma
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 9.16% | 0.89% | €11.61M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.03% | 0.35% | €1.21B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.80% | 0.25% | €44.3M |
Show 5 more
| Xtrackers S&P Europe ex UK UCITS ETF 1DXUEK | 0.13% | 0.09% | €530.6M |
| L&G Europe ex UK Equity UCITS ETFETLN | 0.11% | 0.10% | €458.82M |
| Amundi Prime Europe UCITS ETF DR (D)PR1E | 0.09% | 0.05% | €750.21M |
| Amundi Prime All Country World UCITS ETF AccWEBN | 0.01% | 0.07% | €8.65B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.01% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.